EPIRUS Biopharmaceuticals, Inc. (Epirus) is a biopharmaceutical company. The Company focuses on biosimilars, which are biologic drugs. Its segment is the development and commercialization of biosimilar monoclonal antibodies for emerging markets. The Company's products include BOW015, a biosimilar version of Remicade, which is a monoclonal antibody against tumor necrosis factor alpha (TNF-a); BOW050, a biosimilar version of Humira, which is an inhibitor of TNF-a used to treat inflammatory diseases; BOW070, a biosimilar version of Actemra, which is an immunosuppressive drug for the treatment of rheumatoid arthritis, polyarticular arthritis and systemic juvenile idiopathic arthritis; BOW090, a biosimilar version of STELARA, which is an immunosuppressant drug for the treatment of plaque psoriasis and psoriatic arthritis; BOW100, a biosimilar version of SIMPONI, which is an inhibitor of TNF-a, and BOW080, a biosimilar version of Soliris, which is used to treat ultra-rare blood disorders.
Industry, Sector and Symbol:
- Trailing P/E Ratio:
- P/E Growth:
- Net Margins: -2,025.65%
- Return on Equity: -208.66%
- Return on Assets: -97.67%
Frequently Asked Questions for Epirus Biopharmaceuticals (NASDAQ:CRXX)
What is Epirus Biopharmaceuticals' stock symbol?
Epirus Biopharmaceuticals trades on the NASDAQ under the ticker symbol "CRXX."
Who are some of Epirus Biopharmaceuticals' key competitors?
Some companies that are related to Epirus Biopharmaceuticals include Partnership Assurance Group PLC (PA), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Hospira (HSP), Smith & Nephew plc (SN), Omnicare (OCR), Valeant Pharmaceuticals Intl (VRX), NMC Health PLC (NMC), Health Net (HNT), Mediclinic International PLC (MDC), Patheon NV (PTHN), ConvaTec Group PLC (CTEC), Catalent (CTLT), Puma Biotechnology (PBYI), WuXi PharmaTech (Cayman) (WX), Cotiviti Holdings (COTV) and Hikma Pharmaceuticals Plc (HIK).
Who are Epirus Biopharmaceuticals' key executives?
Epirus Biopharmaceuticals' management team includes the folowing people:
- Robert Ticktin, Senior Vice President, General Counsel, Secretary
- Vincent E. Aurentz, Chief Business Officer
How do I buy Epirus Biopharmaceuticals stock?
MarketBeat Community Rating for Epirus Biopharmaceuticals (NASDAQ CRXX)MarketBeat's community ratings are surveys of what our community members think about Epirus Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Shares of Epirus Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
Consensus Ratings for Epirus Biopharmaceuticals (NASDAQ:CRXX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Epirus Biopharmaceuticals (NASDAQ:CRXX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Epirus Biopharmaceuticals (NASDAQ:CRXX)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Epirus Biopharmaceuticals (NASDAQ:CRXX)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Epirus Biopharmaceuticals (NASDAQ:CRXX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Epirus Biopharmaceuticals (NASDAQ:CRXX)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Epirus Biopharmaceuticals (NASDAQ:CRXX)
Latest Headlines for Epirus Biopharmaceuticals (NASDAQ:CRXX)
No headlines for this company have been tracked by MarketBeat.com
Epirus Biopharmaceuticals (CRXX) Chart for Tuesday, September, 19, 2017